MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 326973 | Name: Pimavanserin tartrate
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pimavanserin, also known as ACP-103, is a non-dopaminergic atypical antipsychotic for the treatment of Parkinson's disease psychosis and schizophrenia. Pimavanserin has a unique mechanism of action relative to other antipsychotics, behaving as a selective inverse agonist of the serotonin 5-HT2A receptor, with 40-fold selectivity for this site over the 5-HT2C receptor and no significant affinity or activity at the 5-HT2B receptor or dopamine receptors. It was approved by the FDA to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson's disease on April 29, 2016.

Chemical Structure

Pimavanserin tartrate
Pimavanserin tartrate
CAS#706782-28-7 (tartrate)

Theoretical Analysis

MedKoo Cat#: 326973

Name: Pimavanserin tartrate

CAS#: 706782-28-7 (tartrate)

Chemical Formula: C54H74F2N6O10

Exact Mass: 0.0000

Molecular Weight: 1005.21

Elemental Analysis: C, 64.52; H, 7.42; F, 3.78; N, 8.36; O, 15.92

Price and Availability

Size Price Availability Quantity
100mg USD 150.00 Ready to ship
200mg USD 250.00 Ready to ship
500mg USD 450.00 Ready to ship
1g USD 800.00 Ready to ship
2g USD 1,350.00 Ready to ship
5g USD 2,250.00 2 weeks
10g USD 3,650.00 2 weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
706779-91-1 (free base) 706782-28-7 (tartrate)
Synonym
Pimavanserin tartrate; ACP-103; ACP 103; ACP103; Pimavanserin; trade name: Nuplazid.
IUPAC/Chemical Name
1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea, ((2R,3R)-2,3-dihydroxysuccinate) (2:1)
InChi Key
RGSULKHNAKTFIZ-CEAXSRTFSA-N
InChi Code
InChI=1S/2C25H34FN3O2.C4H6O6/c2*1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21;5-1(3(7)8)2(6)4(9)10/h2*4-11,19,23H,12-18H2,1-3H3,(H,27,30);1-2,5-6H,(H,7,8)(H,9,10)/t;;1-,2-/m..1/s1
SMILES Code
O=C(NCC1=CC=C(OCC(C)C)C=C1)N(CC2=CC=C(F)C=C2)C3CCN(C)CC3.O=C(NCC4=CC=C(OCC(C)C)C=C4)N(CC5=CC=C(F)C=C5)C6CCN(C)CC6.O=C(O)[C@H](O)[C@@H](O)C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# 706779-91-1 ( Pimavanserin ) 706782-28-7 (Pimavanserin tartrate)
Solvent mg/mL mM
Solubility
DMSO 70.0 69.60
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 1,005.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zhang Y, Huang Q, Xu Q, Jia C, Xia Y. Pimavanserin tartrate induces apoptosis and cytoprotective autophagy and synergizes with chemotherapy on triple negative breast cancer. Biomed Pharmacother. 2023 Dec;168:115665. doi: 10.1016/j.biopha.2023.115665. Epub 2023 Oct 11. PMID: 37832400. 2: Ramachandran S, Kaushik IS, Srivastava SK. Pimavanserin: A Novel Autophagy Modulator for Pancreatic Cancer Treatment. Cancers (Basel). 2021 Nov 12;13(22):5661. doi: 10.3390/cancers13225661. PMID: 34830816; PMCID: PMC8616166. 3: Liu ZZ, Liu XN, Fan RC, Jia YP, Zhang QK, Gao XQ, Wang YQ, Yang MQ, Ji LZ, Zhou YQ, Li HL, Li P, Tang B. Identification of pimavanserin tartrate as a potent Ca2+-calcineurin-NFAT pathway inhibitor for glioblastoma therapy. Acta Pharmacol Sin. 2021 Nov;42(11):1860-1874. doi: 10.1038/s41401-021-00724-2. Epub 2021 Aug 6. PMID: 34363007; PMCID: PMC8563877. 4: Soogrim V, Ruberto VL, Murrough J, Jha MK. Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date. Drug Des Devel Ther. 2021 Jan 13;15:151-157. doi: 10.2147/DDDT.S240862. PMID: 33469267; PMCID: PMC7812044. 5: Ramachandran S, Srivastava SK. Repurposing Pimavanserin, an Anti-Parkinson Drug for Pancreatic Cancer Therapy. Mol Ther Oncolytics. 2020 Sep 2;19:19-32. doi: 10.1016/j.omto.2020.08.019. PMID: 33024816; PMCID: PMC7527685. 6: Wang S, Wang Y, Gao S, Zhang Y, Wang H, Zhao L, Bi K, Wang S, Chen X. Development of a UPLC-MS/MS method for determination of pimavanserin tartrate in rat plasma: Application to a pharmacokinetic study. J Pharm Anal. 2017 Dec;7(6):406-410. doi: 10.1016/j.jpha.2017.07.004. Epub 2017 Jul 8. PMID: 29404067; PMCID: PMC5790751. 7: Hussar DA, Dimaculangan CA. Reslizumab, ixekizumab, and pimavanserin tartrate. J Am Pharm Assoc (2003). 2016 Sep-Oct;56(5):595-8. doi: 10.1016/j.japh.2016.08.002. PMID: 27594111. 8: Hermanowicz S, Hermanowicz N. The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease. Expert Rev Neurother. 2016 Jun;16(6):625-33. doi: 10.1586/14737175.2016.1158102. PMID: 26908168. 9: Ancoli-Israel S, Vanover KE, Weiner DM, Davis RE, van Kammen DP. Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers. Sleep Med. 2011 Feb;12(2):134-41. doi: 10.1016/j.sleep.2010.10.004. Epub 2011 Jan 21. PMID: 21256805; PMCID: PMC3137254. 10: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Jul-Aug;32(6):437-61. doi: 10.1358/mf.2010.32.6.1538165. PMID: 20852754. 11: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Oct;30(8):643-72. PMID: 19088949. 12: Abbas A, Roth BL. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmacother. 2008 Dec;9(18):3251-9. doi: 10.1517/14656560802532707. PMID: 19040345. 13: Tomillero A, Moral MA. Gateways to clinical trials. July-August 2008. Methods Find Exp Clin Pharmacol. 2008 Jul-Aug;30(6):459-95. PMID: 18850047.